Arielle Mendel, McGill University

Research

Anca-Associated Vasculitis Anti-Neutrophil Cytoplasm Antibody Drug Safety And Effectiveness End-Stage Kidney Disease Glomerulonephritis Glucocorticoids Methylprednisolone Prospective Study

Latest papers

Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study.
JMIR research protocols · 2026
Management of antineutrophil cytoplasmic antibody vasculitis-associated orbital inflammatory disease: A systematic literature review.
Seminars in arthritis and rheumatism · 2026 · senior author
Patient perspectives on clinical trial participation for novel advanced therapies: a focus group study in systemic lupus erythematosus.
Rheumatology international · 2026

All 38 publications

Latest funding

Personalizing Therapy to Optimize Outcomes by Synthesizing Real-World Evidence and Establishing Patient Preferences
CIHR · 2026 · Co-investigator
$443,700
Dose of Induction Methylprednisolone in Severe ANCA-Associated Vasculitis (DIMeS-AAV)
CIHR · 2025 · Nominated PI
$86,875
Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).
CIHR · 2023 · Co-investigator
$5,222,039

All 4 grants and awards

38 publications.

01

Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study.

Filosa E, Schönenberger N, Essien UR, Gagnon C, Gnjidic D, Kouladjian O'Donnell L, Manias E, McCarthy LM, Moriarty F, Nguyen-Soenen J, Scott S, Steinman MA, Thürmann PA, Wilson MG, Gutman BJ, Mendel A, Trinh E, Lee TC, McDonald EG

JMIR research protocols2026

DOI: 10.2196/92082 PMID: 42398036

02

Management of antineutrophil cytoplasmic antibody vasculitis-associated orbital inflammatory disease: A systematic literature review.

Neary E, Healey K, Clements-Baker M, Makhzoum JP, Mendel A

Seminars in arthritis and rheumatism2026Senior author

DOI: 10.1016/j.semarthrit.2025.152900 PMID: 41456508

03

Patient perspectives on clinical trial participation for novel advanced therapies: a focus group study in systemic lupus erythematosus.

Stein OA, Lee JLF, Vinet E, Mendel A, Pineau CA, Kalache F, Grenier LP, Mielczarek L, Bernatsky S

Rheumatology international2026

DOI: 10.1007/s00296-026-06071-x PMID: 41571944

04

Serum perfluorooctane sulfonate and perfluorooctanoic acid concentrations and longitudinal systemic lupus outcomes.

Zhao N, Rochepeau A, Sauvé S, Mendel A, Vinet E, Verner MA, Rauch J, Pineau CA, Lukasa L, Grenier LP, Kalache F, Bernatsky S

Journal of autoimmunity2026

DOI: 10.1016/j.jaut.2026.103636 PMID: 42753309

05

Artificial Intelligence-Based Online Symptom Assessment Tools for Systemic Lupus Erythematosus Diagnosis: Patient Perspectives.

Stein OA, Lee JLF, Vinet E, Mendel A, Pineau CA, Kalache F, Grenier LP, Bernatsky S

Arthritis care & research2026

DOI: 10.1002/acr.80087 PMID: 42138311

06

A Global Survey of Quinacrine Use in Systemic and Cutaneous Lupus Erythematosus.

Aly S, Parastandehchehr G, Bernatsky S, Vinet É, Arnaud L, Costedoat-Chalumeau N, Fortin PR, Reynolds JA, Thorne JC, Touma Z, Wallace D, Werth VP, Singer W, Mendel A

The Journal of rheumatology2026Senior author

DOI: 10.3899/jrheum.2025-0757 PMID: 41326167

07

Biosimilar Rituximab in ANCA‐Associated Vasculitis Compared to the Originator: A Multicenter Cohort Study

Mendel A, Barra L, Behlouli H, Bernatsky S, Clifford AH, Tervaert JWC, Dehghan N, Fifi‐Mah A, Makhzoum J, Meunier R

ACR Open Rheumatology2026First author

DOI: 10.1002/acr2.90119

08

Values, preferences, and informational needs of individuals living with ANCA-associated vasculitis: a systematic review

Junek M, Choi S, Qi Y, Al-Magooshi ASA, Guyatt G, Thabane L, Mendel A, Khalidi N, Walsh M

Rheumatology Advances in Practice2026

DOI: 10.1093/rap/rkag057

09

Clinician views concerning the prevalence and impact of granulomas on the diagnosis, management, and outcomes of ANCA-associated vasculitis

Junek M, Fussner LA, Mendel A, Jayne D, Merkel PA, Walsh M

Rheumatology2026

DOI: 10.1093/rheumatology/keaf585

10

Parvovirus B19-Associated Large-Vessel Vasculitis in an Immunocompromised Patient.

Aw M, Lee TC, Mendel A, Colmegna I

The Journal of rheumatology2025

DOI: 10.3899/jrheum.2025-0514 PMID: 40816734

Personalizing Therapy to Optimize Outcomes by Synthesizing Real-World Evidence and Establishing Patient Preferences

Co-investigatorCIHR2026Project Grant

Principal investigators: Bernatsky, Sasha R; Hazlewood, Glen S

Keywords: Drug Effectiveness; Drug Safety; Health Outcomes Research; Patient Preferences; Rheumatology; Systemic Lupus

$443,700

Dose of Induction Methylprednisolone in Severe ANCA-Associated Vasculitis (DIMeS-AAV)

Nominated PICIHR2025Project Grant

Principal investigators: Mendel, Arielle; Walsh, Michael W

Keywords: Anca-Associated Vasculitis; Anti-Neutrophil Cytoplasm Antibody; Drug Safety And Effectiveness; End-Stage Kidney Disease; Glomerulonephritis; Glucocorticoids; Methylprednisolone; Prospective Study; Serious Infections

$86,875

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Co-investigatorCIHR2023Operating Grant: Clinical Trials Projects

Principal investigators: Sapir-Pichhadze, Ruth; Stalker, Leanne; Colmegna, Ines; Costiniuk, Cecilia T; Suri, Rita

Keywords: Cellular Immunity; Cost Effectiveness; Covid-19; Humoral Immunity; Immunogenicity; Influenza; Neutralization; Quality Of Life; Safety; Vaccine

$5,222,039

Immunogenicity and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial).

Co-investigatorCIHR2023Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Sapir-Pichhadze, Ruth; Stalker, Leanne; Colmegna, Ines; Costiniuk, Cecilia T; Suri, Rita

Keywords: Cellular Immunity; Cost Effectiveness; Covid-19; Humoral Immunity; Immunogenicity; Influenza; Neutralization; Quality Of Life; Safety; Vaccine

$1,305,510

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Medicine
Department of Medicine
Institute of Health Policy, Management, and Evaluation
Rheumatology
Immunology and Rheumatology
Statistics and Actuarial Science
Internal Medicine
Other

1 shared papers, latest 2024

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: Anca-Associated Vasculitis Dear Professor Mendel, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Identification of Potentially Inappropriate Medications for Adults Below 65 Years: Protocol for a Modified Delphi Study." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Dose of Induction Methylprednisolone in Severe ANCA-Associated Vasculitis (DIMeS-AAV)" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]